LBA1 - Intismeran autogene (개인맞춤형 tumor neoantigen) - mRNA cancer vaccine/INT - Moderna / Merck
LBA2 - Enfortumab vedotin (Nectin-4) - ADC - Astellas·Pfizer
LBA3 - Tarlatamab (DLL3×CD3) - Bispecific T-cell engager - Amgen
LBA4 - Darolutamide (Androgen receptor) - Small-molecule AR antagonist - Orion Pharma / Bayer
LBA5 - Divarasib (KRAS G12C) - Small-molecule covalent inhibitor - Roche
LBA6 - Savolitinib (MET) - Small-molecule TKI - HUTCHMED / AstraZeneca
LBA7 - Sonesitatug vedotin, AZD0901/CMG901 (CLDN18.2) - ADC - KYM Biosciences / AstraZeneca
LBA8 - Ivonescimab (PD-1×VEGF) - Bispecific antibody - Akeso / Summit Therapeutics
LBA9 - Risvutatug rezetecan, HS-20093/GSK5764227 (B7-H3) - ADC - Hansoh Pharma / GSK
LBA10 - 여러 immune checkpoint inhibitors (PD-1/PD-L1 등) - Monoclonal antibody/ICI - Academic trial, UNICANCER
LBA11 - Sacituzumab tirumotecan, SKB264/MK-2870 (TROP2) - ADC - Kelun-Biotech / Merck
LBA12 - Pembrolizumab (PD-1) - Monoclonal antibody/ICI - Merck